COVID-19 is an emerging, rapidly evolving siituation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

News and Announcements

All | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010

Displaying 141 - 160 of 262
CPTAC Develops PepQuery for Novel Peptide Identification and Validation

Integrative proteogenomic methods use mass spectrometry (MS)-based proteomic database for identifying new genomic alterations and validating novel protein sequences as potential disease biomarkers or therapeutic targets. The customized database approach is time consuming and not feasible for real-...


Update on Behalf of NCI’s Cancer Imaging Program (New CPTAC Histopathology Images)

Built on a continuous partnership between National Cancer Institute’s (NCI’s) Cancer Imaging Program and the Clinical Proteomic Tumor Analysis Consortium (CPTAC), NCI’s The Cancer Imaging Archive (TCIA) releases a newly improved CPTAC histopathology interface. The interface hosts histopathology...


NCI Proteomics Assay Portal Releases 660 Mouse MRM-MS Plasma Assays

Built on a continuous partnership between National Cancer Institute (NCI) and the University of Victoria Genome British Columbia Proteomics Centre, NCI’s CPTAC Assay Portal releases 660 mouse multiple reaction monitoring-mass spectrometry (MRM-MS) plasma assays...


ICPC Korea University Team Proteogenomically Characterizes Early-Onset Gastric Cancer

The incidence of early-onset gastric cancer (EOGC), a type of cancer that occurs in younger patients and found throughout the stomach, is markedly elevated in the Republic of Korea. As a country with the highest rates worldwide in both sexes, there is a need to identify molecular signatures...


Proteogenomics Approach Identifies DPYSL3 Gene in Triple-Negative Breast Cancer

Claudin-Low (CLOW) tumors are classified as a subset of triple-negative breast cancers and account for a minority of breast cancer cases. But until now, there has been little study of their unique biological features. Understanding the biology of CLOW tumors is important for designing targeted...


Final Announcement: PrecisionFDA NCI-CPTAC Multi-omics Challenge Ends in Four Days

The NCI-CPTAC Multi-omics Enabled Sample Mislabeling Correction Challenge sub-challenge 2 closes on December 19 at 07:59:59 UTC. Just four days left to submit your computational algorithms. Remember, if...


CPTAC Contributes to In-Depth Profiling of CAR T-Cell Signaling

CAR T-cells, which are immune cells reprogrammed to fight cancer, are promising novel cancer therapies to treat certain types of tumors. But, the underlying biological pathways that lead to remission or toxicity are not fully understood. In a study published in...


PrecisionFDA NCI-CPTAC Multi-Omics Challenge Deadline Approaching

The NCI-CPTAC Multi-omics Enabled Sample Mislabeling Correction Challenge sub-challenge 2 closes on December 19 at 07:59:59 UTC. Just two weeks left to submit your compuational algorithms. Remember, if you did not participate in sub-challenge 1, you can still participate in sub-challenge 2.


PrecisionFDA NCI-CPTAC Multi-Omics Challenge Launches Sub-Challenge 2

The second data release for the NCI-CPTAC Multi-omics Enabled Sample Mislabeling Correction Challenge has launched!  If you did not participate in sub-challenge 1 (submission 1), you can still participate in sub-challenge 2 (submission 2).


CPTAC Contributes to the Identification of a Novel Pharmacodynamic Biomarker for Clinical Trial Use

Several ongoing Phase I clinical trials are assessing the safety and tolerability of ATM (ataxia-telangiectasia mutated) and ATR (ataxia-telangiectasia and Rad3-Related) inhibitors when administered alone or in combination with existing therapies. ATM and ATR are attractive therapeutic targets in...


PrecisionFDA NCI-CPTAC Multi-Omics Challenge Updates

The security of precisionFDA users’ personal information and data is of critical importance. To strengthen the safeguards already in place, precisionFDA will be introducing several changes to achieve compliance with the FedRAMP and FISMA Moderate security standards. These changes will take effect...


CPTAC Releases UCEC, ccRCC Discovery Data and Other Study Datasets

The Clinical Proteomic Tumor Analysis Consortium (CPTAC) is releasing the latest proteomic discovery datasets for Uterine Corpus Endometrial Carcinoma (UCEC) and Clear Cell Renal Cell Carcinoma (ccRCC). CPTAC has previously demonstrated how proteogenomics reveals new insights into cancer biology....


CPTAC Develops Fit-for-Purpose Immuno-MRM Assay for FANCD2 Protein Modification Involved in DNA Damage

Fanconi anemia (FA) is a rare inherited disorder characterized by progressive bone marrow failure and an increased risk of developing certain types of cancer. The FA pathway consists of a network of 21...


Cancer Has No Borders – NCI Video Release Highlights the International Cancer Proteogenome Consortium

The Office of Cancer Clinical Proteomics Research of the National Cancer Institute (NCI), part of the National Institutes of Health, announces the release of a video titled, “International Cancer Proteogenome Consortium (ICPC)”. Launched during the 2018 Human Proteome Organization World Congress, the...


The precisionFDA NCI-CPTAC Multi-Omics Challenge is Open for Submissions

The National Cancer Institute in partnership with the Food and Drug Administration is pleased to announce the launch of the precisionFDA NCI-CPTAC Multi-Omics Challenge. The aim of this crowd-...


CPTAC and FDA Discuss Upcoming Computational Challenge in the Journal Nature Medicine

Multidimensional multi-omics datasets from The Cancer Genome Atlas (TCGA), the Clinical Proteomic Tumor Analysis Consortium (CPTAC), and similar initiatives are becoming a powerful approach to...


CPTAC Evaluates SEER Repository Tissues as a Resource for Population-Based Cancer Proteomic Studies

Next-generation mass spectrometry (NGMS) has become a powerful tool for protein identification and quantification from prospectively collected fresh frozen or optimal cutting temperature embedded specimens. However, limitations due to supply, accessibility, and delay of clinical information and...


Get Ready to Join the precisionFDA NCI-CPTAC Multi-Omics Challenge

In biomedical research, sample mislabeling or incorrect annotation has been a long-standing problem that contributes to irreproducible results and invalid conclusions. These problems are particularly prevalent in large scale multi-omics studies where human errors could arise during sample...


CPTAC Optimizes Proteomic Workflow for Cancer Research

In recent years, proteomic technologies have emerged as invaluable tools in cancer research. Next-generation mass spectrometry (NGMS) is being used to study cancer biology, while providing the cancer research community with a growing body of biological knowledge that may lead to more effective drug...


Agarwal Laboratory Demonstrates a Potential Therapeutic Strategy for Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a heterogenous malignancy that stems from the production of abnormal white blood cells, platelets, or red blood cells in the bone marrow. It is estimated that 19,520 new...


Pages